Show simple item record

dc.contributor.authorThatcher, Nick
dc.contributor.authorSharma, H
dc.contributor.authorHarrison, R
dc.contributor.authorSmith, A
dc.contributor.authorZaki, A
dc.contributor.authorMcAuliffe, C A
dc.contributor.authorCrowther, Derek
dc.contributor.authorFox, Brian W
dc.date.accessioned2010-07-21T14:06:32Z
dc.date.available2010-07-21T14:06:32Z
dc.date.issued1982
dc.identifier.citationBlood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease. 1982, 9 (1):13-6 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704
dc.identifier.pmid6890414
dc.identifier.doi10.1007/BF00296754
dc.identifier.urihttp://hdl.handle.net/10541/108081
dc.description.abstractThe blood clearances of three platinum compounds, cis-dichlorodiammine platinum II (DDP), cis, trans-dichloro-dihydroxy-bis-(isopropylamine) platinum IV (CHIP), and cis-dichloro-bis-cyclopropylamine platinum II (CP), were determined in nine patients with malignant disease. The complexes were prepared using radioactive platinum (191Pt and 193Pt). A 10-mu Ci dose of each complex, containing the equivalent of 1-2 mg elemental platinum, was injected IV into groups of three patients. Serial blood and urine samples were collected over 72 h. No obvious difference was found between the three complexes for blood clearance, median t1/2a being 16.8 (range 11.2-23.5) min and median t1/2 beta 89 (range 63.7-127) h. The urinary excretion was greatest for CHIP, 60% of injected dose as against 42.6% for CP and 38.8% for DDP. Differences in renal excretion of DDP analogues could indicate potentially less nephrotoxic agents. The use of radioactive Pt will allow in vivo dynamic imaging of the distribution of platinum compounds in areas of interest.
dc.language.isoenen
dc.subjectCanceren
dc.subjectCancer Metastasisen
dc.subject.meshAged
dc.subject.meshCisplatin
dc.subject.meshFemale
dc.subject.meshHalf-Life
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Metastasis
dc.subject.meshNeoplasms
dc.subject.meshOrganoplatinum Compounds
dc.subject.meshPlatinum
dc.subject.meshRadioisotopes
dc.subject.meshSolubility
dc.subject.meshTime Factors
dc.titleBlood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital, Wilmslow Road, M20 9BX Manchester.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
html.description.abstractThe blood clearances of three platinum compounds, cis-dichlorodiammine platinum II (DDP), cis, trans-dichloro-dihydroxy-bis-(isopropylamine) platinum IV (CHIP), and cis-dichloro-bis-cyclopropylamine platinum II (CP), were determined in nine patients with malignant disease. The complexes were prepared using radioactive platinum (191Pt and 193Pt). A 10-mu Ci dose of each complex, containing the equivalent of 1-2 mg elemental platinum, was injected IV into groups of three patients. Serial blood and urine samples were collected over 72 h. No obvious difference was found between the three complexes for blood clearance, median t1/2a being 16.8 (range 11.2-23.5) min and median t1/2 beta 89 (range 63.7-127) h. The urinary excretion was greatest for CHIP, 60% of injected dose as against 42.6% for CP and 38.8% for DDP. Differences in renal excretion of DDP analogues could indicate potentially less nephrotoxic agents. The use of radioactive Pt will allow in vivo dynamic imaging of the distribution of platinum compounds in areas of interest.


This item appears in the following Collection(s)

Show simple item record